Cargando…
敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理
Leptomeningeal metastasis (LM) is one of the serious complications of advanced non-small cell lung cancer (NSCLC), although the incidence is not high, the clinical symptoms are severe and the prognosis is poor. LM is prone to occur in patients with positive driver gene than negative. At present, the...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467993/ https://www.ncbi.nlm.nih.gov/pubmed/32758347 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.18 |
| _version_ | 1783578130714198016 |
|---|---|
| collection | PubMed |
| description | Leptomeningeal metastasis (LM) is one of the serious complications of advanced non-small cell lung cancer (NSCLC), although the incidence is not high, the clinical symptoms are severe and the prognosis is poor. LM is prone to occur in patients with positive driver gene than negative. At present, the treatment of LM mainly includes molecular targeted therapy, systemic chemotherapy, whole brain radiotherapy, intrathecal chemotherapy and immunotherapy. Although there are many treatments, the efficacy of LM is still unsatisfactory. This article reviews the drug therapy of sensitive driver gene positive NSCLC LM. |
| format | Online Article Text |
| id | pubmed-7467993 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74679932020-09-03 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 Zhongguo Fei Ai Za Zhi 综述 Leptomeningeal metastasis (LM) is one of the serious complications of advanced non-small cell lung cancer (NSCLC), although the incidence is not high, the clinical symptoms are severe and the prognosis is poor. LM is prone to occur in patients with positive driver gene than negative. At present, the treatment of LM mainly includes molecular targeted therapy, systemic chemotherapy, whole brain radiotherapy, intrathecal chemotherapy and immunotherapy. Although there are many treatments, the efficacy of LM is still unsatisfactory. This article reviews the drug therapy of sensitive driver gene positive NSCLC LM. 中国肺癌杂志编辑部 2020-08-20 /pmc/articles/PMC7467993/ /pubmed/32758347 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.18 Text en 版权所有©《中国肺癌杂志》编辑部2020 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
| spellingShingle | 综述 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 |
| title | 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 |
| title_full | 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 |
| title_fullStr | 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 |
| title_full_unstemmed | 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 |
| title_short | 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 |
| title_sort | 敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467993/ https://www.ncbi.nlm.nih.gov/pubmed/32758347 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.18 |
| work_keys_str_mv | AT mǐngǎnqūdòngjīyīnyángxìngfēixiǎoxìbāofèiáinǎomózhuǎnyíyàowùzhìliáodeguǎnlǐ AT mǐngǎnqūdòngjīyīnyángxìngfēixiǎoxìbāofèiáinǎomózhuǎnyíyàowùzhìliáodeguǎnlǐ AT mǐngǎnqūdòngjīyīnyángxìngfēixiǎoxìbāofèiáinǎomózhuǎnyíyàowùzhìliáodeguǎnlǐ AT mǐngǎnqūdòngjīyīnyángxìngfēixiǎoxìbāofèiáinǎomózhuǎnyíyàowùzhìliáodeguǎnlǐ |